MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

Store in airtight containers. Protect from light.

Provenance

This compatibility recommendation is derived from Ismo 20 tablets (Esteve Pharmaceuticals Ltd).

Stability Notes

Store in an airtight container.

Provenance

This compatibility recommendation is derived from Kivexa 600mg/300mg tablets (ViiV Healthcare UK Ltd).

Stability Notes

Protect from light.

Provenance

This compatibility recommendation is derived from Lamisil 250mg tablets (Novartis Pharmaceuticals UK Ltd).

Stability Notes

Store in tight, light-resistant containers.

Provenance

Compatibility recommendation derived from Nadolol 80mg tablets (Neon Healthcare Ltd).

Stability Notes

Protect from moisture.

Provenance

This compatibility recommendation is derived from Galvus 50mg tablets (Novartis Pharmaceuticals UK Ltd).

Stability Notes

Protect from moisture and light.

Provenance

This compatibility recommendation is derived from Famvir 125mg tablets (Phoenix Labs Ltd).

Stability Notes

No special requirements for storage.

Provenance

This compatibility recommendation is derived from Vimpat 50mg tablets (UCB Pharma Ltd).

Stability Notes

Protect from moisture. Store in an airtight container.

Provenance

This compatibility recommendation is derived from Yentreve 40mg gastro-resistant capsules (Eli Lilly and Company Ltd).

Stability Notes

No special requirements for storage.

Provenance

This compatibility recommendation is derived from Vimpat 100mg tablets (UCB Pharma Ltd).

Stability Notes

No special requirements for storage.

Provenance

This compatibility recommendation is derived from Vimpat 150mg tablets (UCB Pharma Ltd).

Stability Notes

Store in an airtight container. Protect from moisture. Max 28 days in MCA.

Provenance

This compatibility recommendation is derived from Cymbalta 60mg gastro-resistant capsules (Eli Lilly and Company Ltd).

Print this list

Medicines under this category are suitable for use inside MCAs, although this is likely to be an off-label use.
Medicines under this category can theoretically be used inside an MCA; however, mitigations may need to be considered.
Medicines under this category are not suitable for use inside MCAs.
We do not have stability information for these medicines and therefore cannot make a recommendation on suitability in an MCA.